XLTA

What XLTA does

XLTA is a privately held medical device company headquartered in Atlanta, Georgia that designs, manufactures, and distributes advanced wound care dressings under the XLTA® CURE Wound Care Range brand. The company sells three core product variants — MAX 340gsm (lightweight), SUPER 640gsm (flagship versatile), and ACE 750gsm (high-absorbency for heavy exudate) — built around its proprietary Hydrocapillary Triple-Action mechanism, which combines hydrocapillary flow (rapid absorption and omnidirectional dispersion), electrostatic charge (attraction of negatively charged bacteria and MMPs), and proteolytic enzyme balance (modulation of excessive protease activity) within a 2-in-1 structure featuring dual non-adherent layers. The dressings are composed predominantly of natural fibers and are chemical-free and unmedicated, intended for use in both chronic wounds (diabetic ulcers, leg ulcers, venous stasis ulcers) and acute wounds (burns, surgical wounds, traumatic injuries).

The company was founded by Kobie Mouton, who brings over 30 years of wound care industry experience and previously co-invented Drawtex. XLTA generates revenue primarily through one-time product sales to healthcare providers, wound care clinics, and podiatrists via a distributor-led go-to-market model rather than direct sales. Active distribution partners include Total Ancillary and Pivotal Med Supply in the United States, Xlta Woundcare (Pty) Ltd and AD Systems and Consulting (Pty) Ltd in South Africa, and XLTA Medical Technologies Co Ltd in Taiwan. The company is actively recruiting additional global distribution agents and agency partners through an online application portal on its website. Marketing channels include LinkedIn, YouTube product demonstrations, industry conference participation (notably SAWC Fall 2025 in Las Vegas), PR support from MedTech Momentum, and direct consultation booking.

XLTA operates as XLTA US LLC in Georgia and maintains regional distribution entities in South Africa and Taiwan, with 11-50 employees total. The company is founder-owned and controlled, with no disclosed external institutional investment or funding rounds. Its US market entry was formalized at SAWC Fall 2025 in September 2025, followed by a strategic distributor partnership with Total Ancillary in February 2026. Clinical evidence cited includes an academic poster from Stellenbosch University and retrospective case studies, with the founder's prior Drawtex product having served tens of thousands of patients globally.

Name

XLTA

Legal name

XLTA US LLC

Website

https://xltacure.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

XLTA is a privately held medical device company that designs and distributes the XLTA® CURE wound care range — advanced hydrocapillary dressings for chronic and acute wounds — selling through distributors to healthcare providers in the US, South Africa, and Taiwan.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Dressings

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)

Keywords

• Advanced wound care
• Hydrocapillary dressings
• Wound exudate management
• Medical device bandages
• Chronic wound dressings

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Medical Device Product Sales: XLTA generates revenue through the sale of its hydrocapillary wound care dressings. The product range includes MAX 340gsm, SUPER 640gsm, and ACE 750gsm variants sold to healthcare providers, clinicians, and through distributor networks across North America, South Africa, and Asia-Pacific.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels5 records

Core offering

XLTA designs, manufactures, and sells the XLTA CURE Wound Care Range, a line of advanced hydrocapillary, non-adherent wound dressings used by healthcare providers to manage exudate, bioburden, and wound bed preparation across chronic and acute wounds. The range includes three super-absorbent variants (MAX 340gsm, SUPER 640gsm, and ACE 750gsm) built around a proprietary Hydrocapillary Triple-Action mechanism that combines capillary flow, electrostatic attraction of bacteria and MMPs, and proteolytic enzyme balance within a 2-in-1 primary/secondary dressing structure.

Product overview

XLTA offers the XLTA® CURE Wound Care Range, an advanced wound care solution combining hydrocapillary and hydroconductive technology with superior exudate management and infection control. The product line consists of three super-absorbent, non-adherent wound dressing variants: MAX 340gsm (lightweight, for precision applications with light to moderate exudate), SUPER 640gsm (the flagship versatile product for diverse wound care scenarios), and ACE 750gsm (heavyweight for high-exudate and complex wounds). All dressings feature a 2-in-1 triple action mechanism combining hydrocapillary flow, electrostatic charge, and proteolytic enzyme balance, designed for use as both primary and secondary dressings.

Differentiator

Problem solved

Functional benefit

Brands

• XLTA CURE Wound Care Range: Advanced wound care product line featuring hydrocapillary triple-action technology for exudate management, infection control, and tissue regeneration.

Products and services

• XLTA MAX 340gsm A lightweight and conformable Hydrocapillary Triple-Action wound dressing engineered for precision in challenging wound care scenarios, designed for light to moderate exudate management in complex contours and hard-to-dress areas. Intended for healthcare providers managing chronic and acute wounds.
• XLTA SUPER 640gsm The flagship XLTA wound dressing offering versatile and dependable Hydrocapillary Triple-Action performance for diverse clinical environments, functioning as both primary and secondary dressing for chronic and acute wound management. Intended for hospitals, wound care clinics, podiatrists, and healthcare professionals.
• XLTA ACE 750gsm A high-performance heavyweight XLTA wound dressing engineered for complex wounds with heavy exudate, designed as both primary and secondary dressing for maximum absorbency and protection in demanding clinical scenarios. Targeted at healthcare providers treating severe chronic and acute wounds.

Quantifiable outcome

• Atraumatic, painless dressing removal
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered key and secondary.

• Total AncillarykeyChannel Partner/ Reseller/ Distributor · 4 February 2026XLTA announced a strategic distributor partnership with Total Ancillary, a Texas-based healthcare distribution company recognized as a trusted influencer in the wound care space. The partnership expands distribution of XLTA's chemical-free, non-adherent wound dressing across Total Ancillary's provider and clinician network in the U.S. market.
• Pivotal Med SupplykeyChannel Partner/ Reseller/ DistributorPivotal Med Supply is a U.S.-based medical supply distributor for XLTA wound care products. Contact: Tel: +1-866-510-0040.
• Xlta Woundcare (Pty) LtdkeyChannel Partner/ Reseller/ DistributorXlta Woundcare (Pty) Ltd serves as the distributor for XLTA products in South Africa and African countries. Located at 8 Dias Street, Dan Pienaar, Bloemfontein, South Africa, 9301.
• AD Systems and Consulting (Pty) LtdsecondaryChannel Partner/ Reseller/ DistributorAD Systems and Consulting (Pty) Ltd is a consulting and distribution partner for XLTA in South Africa. Located at 2 Claassen Close, Silver Lakes, Pretoria, Gauteng, South Africa, 0054.
• XLTA Medical Technologies Co LtdkeyChannel Partner/ Reseller/ DistributorXLTA Medical Technologies Co Ltd serves as the distributor for XLTA products in the Far East, specifically Taiwan. Located at 5F, No.698 Zhongyang Rd., Xinzhuang Dist., New Taipei City 24251, Taiwan (R.O.C.).

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Mölnlycke Health Care: Major wound care incumbent behind Mepilex foam/silicone dressings; competes with XLTA for the same chronic and acute wound exudate management use cases across global hospital formularies.
• Smith & Nephew: Global medical device leader whose Advanced Wound Management portfolio (Allevyn foam dressings, PICO NPWT) directly competes with XLTA's hydrocapillary dressings in hospital and community wound care channels.
• 3M Health Care (Solventum): Now operating as Solventum, the Tegaderm and V.A.C. dressing/negative-pressure portfolios compete with XLTA across the same hospital advanced wound care category in the U.S. and globally.
• ConvaTec: Diversified wound, ostomy and continence company whose Aquacel hydrofiber dressings are among the most direct competitors to XLTA's super-absorbent fiber dressings for exudate and bioburden management.
• Coloplast: Global wound and skin care company with Biatain foam and other advanced dressings that compete with XLTA in chronic wound management, particularly through hospital and home-care channels.

Direct peers

• MiMedx: Public pure-play wound care and surgical recovery company marketing EpiFix and other amniotic tissue products for chronic wounds, directly overlapping XLTA's chronic wound use cases and clinician customers.
• Organogenesis: Pure-play advanced wound care and regenerative medicine company whose Apligraf, Dermagraft and amniotic membrane products compete with XLTA's dressings in chronic wound and outpatient wound clinic settings.
• Urgo Medical: Specialist wound care subsidiary of Urgo Group offering UrgoStart and other advanced dressings for chronic wounds; competes with XLTA's dressings in European and selected international hospital channels.
• Integra LifeSciences: Specialty medical device company with a meaningful wound care franchise (Integra Dermal Regeneration Template, amniotic tissue products) that competes with XLTA in advanced wound healing for complex and chronic wounds.

Regional players

• Hartmann Group: European-headquartered wound care manufacturer whose Mepore, Atrauman and other advanced dressings compete with XLTA in EMEA and selected international markets where XLTA's distributor partners are building presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@XLTACure
• LinkedInlinkedin.com/company/xlta-cure
• Xx.com/XLTACure

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XLTA